Golden
LoginSign Up
ImStar Therapeutics

ImStar Therapeutics

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien.

ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.

Funding

Seed Round

On June 8, 2016 ImStar Therapeutics closed their seed funding round with $1.8 million in funding from BDC Venture Capital and Accel-Rx Health Sciences Accelerator.

Timeline

People

Name
Role
Related Golden topics

Agnes Chan

COO

Daniel Wattier

Co-Founder & CEO

David Hunt

Senior Vice President, Research and Development

Jean Pierre Julien

Co-Founder & CSO

Jeff Charpentier

CFO

Julia Levy

Board Chair

Further reading

Title
Author
Link
Type

ImStar Therapeutics Selects Lead Drug Candidate for ALS

ImStar Therapeutics

News

StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer

StemCells, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References